Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Nod For Loxo/Bayer Tissue Agnostic Drug Marks Paradigm Shift In Cancer

Executive Summary

Vitrakvi is effective against a wide variety of cancers driven by NTRK fusion. But finding the patients who will benefit will be a challenge, given there are expected to be only around 2,500 to 3,000 new cases in the US and testing for the mutation is uncommon. 

Advertisement

Related Content

Bayer Still Confident Of Future Prospects Post-Xarelto
Analysts Weigh Up Benefits Of Big Bayer Restructuring
Big Changes At Bayer With Animal Health Exit And 12,000 Jobs Cut
Bayer Files Larotrectinib In EU As LOXO-292 Hurtles Towards The Market
Loxo’s Tissue-Agnostic Approach Brings $400m Upfront From Bayer
Biomarker-Led Claim Is Small Step For Merck's Keytruda, Giant Leap For Cancer Indications

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124236

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel